Jesper Høiland Joins Alva Therapeutics’ Board of Directors
Jesper Høiland, former senior executive at Novo Nordisk with over 30 years of experience, has joined the Board of Directors at Alva Therapeutics as of December 3, 2025.
Høiland has held executive roles including EVP and President at Novo Nordisk and previously served as President and CEO of Radius Health and Global Commercial Officer at Ascendis Pharma.
He currently chairs SciBase Holding AB and serves on the boards of ALK-Abelló A/S, Flen Health SA, and Allarity Therapeutics.
Alva Therapeutics is developing a novel oral incretin secretagogue therapy for Type 2 diabetes and obesity, planning to start US clinical trials in 2026.
Mir Imran, CEO and Chairman of Alva Therapeutics, emphasized Høiland's extensive experience in pharmaceutical product launches in the diabetes area and his value for Alva's clinical progress.
Jesper Høiland himself expressed strong belief in Alva's potential to change the standard of care for Type 2 diabetes and obesity.
Alva Therapeutics is based in Milpitas, California and is an InCube Labs company founded by Mir Imran.